First-line Treatment Clinical Trials

5 recruiting

First-line Treatment Trials at a Glance

11 actively recruiting trials for first-line treatment are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Beijing, Chengdu, and Frankfurt. Lead sponsors running first-line treatment studies include Jiangsu HengRui Medicine Co., Ltd., Changchun GeneScience Pharmaceutical Co., Ltd., and CatalYm GmbH.

Browse first-line treatment trials by phase

Treatments under study

About First-line Treatment Clinical Trials

Looking for clinical trials for First-line Treatment? There are currently 5 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new First-line Treatment trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about First-line Treatment clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

Unresectable or Metastatic Hepatocellular CarcinomaChild-Pugh A Hepatocellular CarcinomaFailure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
CatalYm GmbH104 enrolled2 locationsNCT07219459
Recruiting
Phase 2

Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial

Nasopharyngeal Carcinoma (NPC)First-line Treatment Failure Nasopharyngeal Carcinoma
Sun Yat-sen University41 enrolled1 locationNCT07101744
Recruiting
Phase 3

Irinotecan Hydrochloride Liposome Injection (II)in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Metastatic Pancreatic Cancer

First-line Treatment of Metastatic Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.662 enrolled1 locationNCT07238283
Recruiting
Phase 1

Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases

First-line TreatmentColorectal Liver Metastases
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.7 enrolled1 locationNCT07117435
Recruiting
Phase 3

Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of Subjects With HER2-positive Recurrent or Metastatic Breast Cancer.

First-line Treatment of HER2-positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc.880 enrolled1 locationNCT05838066
Recruiting
Phase 2

Testing a Functional Precision Medicine Approach to Select Chemotherapy for Metastatic Colorectal Cancer (COSENSE-1)

Metastatic Colorectal CancerFirst-line TreatmentOrganoids+3 more
St. Olavs Hospital148 enrolled1 locationNCT06907342
Recruiting
Not Applicable

Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue

Cancer-related Fatigue, Gastric Cancer,Colorectal Cancer,Nano-crystalline Megestrol Acetate,Megestrol Acetate,First-line Treatment
Changchun GeneScience Pharmaceutical Co., Ltd.76 enrolled1 locationNCT06830018
Recruiting
Phase 1Phase 2

A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

Renal Cell CarcinomaFirst-line Treatment
Hao Zeng33 enrolled1 locationNCT05808608
Recruiting

Can Digitally Delivered First-line Osteoarthritis Treatment Improve Equal Access to Care

First-line TreatmentOsteoarthritisHealth Services Accessibility
Joint Academy50,000 enrolled1 locationNCT06148779
Recruiting
Phase 3

HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

First-line Treatment of Advanced Pancreatic Cancer
Jiangsu HengRui Medicine Co., Ltd.778 enrolled1 locationNCT05751850
Recruiting
Phase 3

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

HER2-positive Metastatic Breast CancerFirst-line Treatment
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University312 enrolled1 locationNCT06278870